You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Caffeine and Parkinson’s Disease: Multiple Benefits and Emerging Mechanisms
|
|---|---|
| Published in |
Frontiers in Neuroscience, December 2020
|
| DOI | 10.3389/fnins.2020.602697 |
| Pubmed ID | |
| Authors |
Xiangpeng Ren, Jiang-Fan Chen |
| Abstract |
Parkinson's disease (PD) is the second most common neurodegenerative disorder, characterized by dopaminergic neurodegeneration, motor impairment and non-motor symptoms. Epidemiological and experimental investigations into potential risk factors have firmly established that dietary factor caffeine, the most-widely consumed psychoactive substance, may exerts not only neuroprotective but a motor and non-motor (cognitive) benefits in PD. These multi-benefits of caffeine in PD are supported by convergence of epidemiological and animal evidence. At least six large prospective epidemiological studies have firmly established a relationship between increased caffeine consumption and decreased risk of developing PD. In addition, animal studies have also demonstrated that caffeine confers neuroprotection against dopaminergic neurodegeneration using PD models of mitochondrial toxins (MPTP, 6-OHDA, and rotenone) and expression of α-synuclein (α-Syn). While caffeine has complex pharmacological profiles, studies with genetic knockout mice have clearly revealed that caffeine's action is largely mediated by the brain adenosine A2A receptor (A2AR) and confer neuroprotection by modulating neuroinflammation and excitotoxicity and mitochondrial function. Interestingly, recent studies have highlighted emerging new mechanisms including caffeine modulation of α-Syn degradation with enhanced autophagy and caffeine modulation of gut microbiota and gut-brain axis in PD models. Importantly, since the first clinical trial in 2003, United States FDA has finally approved clinical use of the A2AR antagonist istradefylline for the treatment of PD with OFF-time in Sept. 2019. To realize therapeutic potential of caffeine in PD, genetic study of caffeine and risk genes in human population may identify useful pharmacogenetic markers for predicting individual responses to caffeine in PD clinical trials and thus offer a unique opportunity for "personalized medicine" in PD. |
X Demographics
The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 2 | 13% |
| Armenia | 1 | 6% |
| United States | 1 | 6% |
| Israel | 1 | 6% |
| Netherlands | 1 | 6% |
| Unknown | 10 | 63% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 16 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 186 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 186 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 21 | 11% |
| Student > Ph. D. Student | 15 | 8% |
| Student > Master | 15 | 8% |
| Researcher | 10 | 5% |
| Student > Postgraduate | 9 | 5% |
| Other | 17 | 9% |
| Unknown | 99 | 53% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 17 | 9% |
| Medicine and Dentistry | 13 | 7% |
| Neuroscience | 10 | 5% |
| Agricultural and Biological Sciences | 8 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 4% |
| Other | 28 | 15% |
| Unknown | 103 | 55% |
Attention Score in Context
This research output has an Altmetric Attention Score of 205. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 March 2024.
All research outputs
#195,742
of 25,844,183 outputs
Outputs from Frontiers in Neuroscience
#90
of 11,721 outputs
Outputs of similar age
#5,472
of 516,045 outputs
Outputs of similar age from Frontiers in Neuroscience
#4
of 364 outputs
Altmetric has tracked 25,844,183 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,721 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.0. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 516,045 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 364 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.